News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apogee Therapeutics, LLC
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
May 06, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
March 25, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
March 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
March 04, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
October 30, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 27, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
September 14, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
August 28, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
August 21, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 07, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
August 02, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 18, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Tickers
APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
July 13, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.